TTTuija Tapaninen

Tuija Tapaninen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tuija Tapaninen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure

    by Anssi J. H. Mykkänen, Päivi Hirvensalo, Kathrin Klein, Dorota Kaminska, Markus Grube, Tuija Tapaninen, Johanna I. Kiiski, Mikko Neuvonen, Ville T. Männistö, Jussi Pihlajamäki, et al.

    This study investigated genetic determinants of the pharmacokinetics of the CYP2C8 index drugs repaglinide and gemfibrozil, and their interaction in healthy participants. Sequencing data from a study with montelukast revealed a novel functional CYP2C8 allele (rs2071426, CYP2C8*19 ), predicted to create an intronic splice donor site. In human liver samples, CYP2C8*19 associated with transcript‐specific changes in CYP2C8 mRNA expression, reduced CYP2C8 protein expression, and decreased enzyme activity. Consistently, participants with the CYP2C8*19 / *19 genotype had 45% greater area under the plasma repaglinide concentration–time curve from time zero to infinity (AUC 0‐∞ ) than participants with CYP2C8*1 / *1 ( P = 1.6 × 10 −4 ). Participants with CYP2C8*1 / *3 had 26% smaller AUC 0‐∞ ( P = 0.0033) and those with CYP2C8*1 / *4 had 51% greater AUC 0‐∞ ( P = 8.2 × 10 −4 ). The fold increase in repaglinide AUC 0‐∞ caused by gemfibrozil was 36% ( P = 1.3 × 10 −4 ) smaller in CYP2C8*19 / *19 participants than in CYP2C8*1 / *1 participants. In a genome‐wide association study (GWAS), SLCO1B1 c.521 T>C (rs4149056) associated with increased repaglinide AUC 0‐∞ ( P = 4.5 × 10 −15 ; n = 172) and SLCO1A2 variants associated with decreased AUC 0‐∞ ( P < 10 −8 ). In a GWAS of repaglinide after gemfibrozil pretreatment, SLCO1C1 variants associated with decreased AUC 0‐∞ ( P < 1.6 × 10 −8 ; n = 66). Participants with the poor function SLCO1B1 genotype showed a 32% smaller fold increase in repaglinide AUC 0‐∞ following gemfibrozil than participants with the normal function SLCO1B1 genotype ( P = 0.0045). This study characterizes CYP2C8*19 as a novel decreased function allele and shows that CYP2C8 and SLCO1B1 genotypes affect the gemfibrozil–repaglinide interaction.

  • Open Access

    Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland

    by Tuija Tapaninen, Vesa Lindström, Olivia Hölsä, Emma-Leena Alarmo, Liisa Ukkola-Vuoti, Kimmo Porkka, Oscar Brück

  • Open Access

    Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics

    by Anssi J. H. Mykkänen, E. Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen, Maria Paile‐Hyvärinen, Tuomas O. Lilius, Tuija Tapaninen, Janne T. Backman, Aleksi Tornio, Mikko Niemi

    A clinical trial was carried out to investigate the pharmacogenetics of single‐dose pravastatin and pitavastatin pharmacokinetics in 173 and 164 healthy participants. Additionally, 96 participants were included from previous pharmacogenetic studies with pravastatin. In a genome‐wide meta‐analysis of pravastatin including all 269 participants, SLCO1B1 c.521T>C (rs4149056) was associated with increased AUC0‐∞ (P = 9.8 × 10−12). Similarly, SLCO1B1 c.521T>C was genome‐wide significantly associated with increased AUC0‐∞ of pitavastatin (P = 9.7 × 10−15). Candidate gene analyses suggested that participants with increased function SLCO1B1 variants had decreased pravastatin exposure. Furthermore, decreased function CYP2C9 variants may increase pitavastatin and pitavastatin lactone exposure. Compared to participants with normal function SLCO1B1 genotype, the AUC0‐∞ of pravastatin was 140% (90% confidence interval: 86–210%; P = 4.7 × 10−8) and 37% (20–56%; P = 1.1 × 10−4) greater in participants with poor and decreased function SLCO1B1 genotype, respectively, while participants with highly increased function SLCO1B1 genotype had a 60% (39–75%; P = 6.0 × 10−4) lower AUC0‐∞. The AUC0‐∞ of pitavastatin was 153% (100–222%; P = 1.6 × 10−9) and 35% (8–69%; P = 0.027) greater in participants with poor and decreased function SLCO1B1 genotype, respectively, than in those with normal function SLCO1B1 genotype. Participants with intermediate metabolizer CYP2C9 genotype had 18% (3–34%; P = 0.046) greater AUC0‐∞ of pitavastatin than those with normal metabolizer CYP2C9 genotype. This study demonstrates the important role of SLCO1B1 in pravastatin and pitavastatin pharmacokinetics and suggests that CYP2C9 variants also affect the pharmacokinetics of pitavastatin.


  • Open Access

    Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden

    by Kari Hemminki, Frantisek Zitricky, Asta Försti, Tuija Tapaninen, Akseli Hemminki, Gunnar Juliusson, Carsten Utoft Niemann

    Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny.


  • Open Access

    Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP

    by Anssi J.H. Mykkänen, E. Katriina Tarkiainen, Suvi Taskinen, Mikko Neuvonen, Maria Paile‐Hyvärinen, Tuomas O. Lilius, Tuija Tapaninen, Kathrin Klein, Matthias Schwab, Janne T. Backman, et al.

    In a genome‐wide association study of atorvastatin pharmacokinetics in 158 healthy volunteers, the SLCO1B1 c.521T>C (rs4149056) variant associated with increased area under the plasma concentration‐time curve from time zero to infinity (AUC0–∞) of atorvastatin (P = 1.2 × 10−10), 2‐hydroxy atorvastatin (P = 4.0 × 10−8), and 4‐hydroxy atorvastatin (P = 2.9 × 10−8). An intronic LPP variant, rs1975991, associated with reduced atorvastatin lactone AUC0–∞ (P = 3.8 × 10−8). Three UGT1A variants linked with UGT1A3*2 associated with increased 2‐hydroxy atorvastatin lactone AUC0–∞ (P = 3.9 × 10−8). Furthermore, a candidate gene analysis including 243 participants suggested that increased function SLCO1B1 variants and decreased activity CYP3A4 variants affect atorvastatin pharmacokinetics. Compared with individuals with normal function SLCO1B1 genotype, atorvastatin AUC0–∞ was 145% (90% confidence interval: 98‐203%; P = 5.6 × 10−11) larger in individuals with poor function, 24% (9‐41%; P = 0.0053) larger in those with decreased function, and 41% (16‐59%; P = 0.016) smaller in those with highly increased function SLCO1B1 genotype. Individuals with intermediate metabolizer CYP3A4 genotype (CYP3A4*2 or CYP3A4*22 heterozygotes) had 33% (14‐55%; P = 0.022) larger atorvastatin AUC0–∞ than those with normal metabolizer genotype. UGT1A3*2 heterozygotes had 16% (5‐25%; P = 0.017) smaller and LPP rs1975991 homozygotes had 34% (22‐44%; P = 4.8 × 10−5) smaller atorvastatin AUC0‐∞ than noncarriers. These data demonstrate that genetic variation in SLCO1B1, UGT1A3, LPP, and CYP3A4 affects atorvastatin pharmacokinetics. This is the first study to suggest that LPP rs1975991 may reduce atorvastatin exposure. [Correction added on 6 April, after first online publication: An incomplete sentence (“= 0.017) smaller in heterozygotes for UGT1A3*2 and 34% (22%, 44%; P × 10−5) smaller in homozygotes for LPP noncarriers.”) has been corrected in this version.]


  • Open Access

    Genomewide Association Study of Simvastatin Pharmacokinetics

    by Anssi J. H. Mykkänen, Suvi Taskinen, Mikko Neuvonen, Maria Paile‐Hyvärinen, E. Katriina Tarkiainen, Tuomas Lilius, Tuija Tapaninen, Janne T. Backman, Aleksi Tornio, Mikko Niemi

    We investigated genetic determinants of single‐dose simvastatin pharmacokinetics in a prospective study of 170 subjects and a retrospective cohort of 59 healthy volunteers. In a microarray‐based genomewide association study with the prospective data, the SLCO1B1 c.521T>C (p.Val174Ala, rs4149056) single nucleotide variation showed the strongest, genomewide significant association with the area under the plasma simvastatin acid concentration‐time curve (AUC; P = 6.0 × 10−10). Meta‐analysis with the retrospective cohort strengthened the association (P = 1.6 × 10−17). In a stepwise linear regression candidate gene analysis among all 229 participants, SLCO1B1 c.521T>C (P = 1.9 × 10−13) and CYP3A4 c.664T>C (p.Ser222Pro, rs55785340, CYP3A4*2, P = 0.023) were associated with increased simvastatin acid AUC. Moreover, the SLCO1B1 c.463C>A (p.Pro155Thr, rs11045819, P = 7.2 × 10−6) and c.1929A>C (p.Leu643Phe, rs34671512, P = 5.3 × 10−4) variants associated with decreased simvastatin acid AUC. Based on these results and the literature, we classified the volunteers into genotype‐predicted OATP1B1 and CYP3A4 phenotype groups. Compared with the normal OATP1B1 function group, simvastatin acid AUC was 273% larger in the poor (90% confidence interval (CI), 137%, 488%; P = 3.1 × 10−6), 40% larger in the decreased (90% CI, 8%, 83%; P = 0.036), and 67% smaller in the highly increased function group (90% CI, 46%, 80%; P = 2.4 × 10−4). Intermediate CYP3A4 metabolizers (i.e., heterozygous carriers of either CYP3A4*2 or CYP3A4*22 (rs35599367)), had 87% (90% CI, 39%, 152%, P = 6.4 × 10−4) larger simvastatin acid AUC than normal metabolizers. These data suggest that in addition to no function SLCO1B1 variants, increased function SLCO1B1 variants and reduced function CYP3A4 variants may affect the pharmacokinetics, efficacy, and safety of simvastatin. Care is warranted if simvastatin is prescribed to patients carrying decreased function SLCO1B1 or CYP3A4 alleles.


  • Open Access

    Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics

    by Päivi Hirvensalo, Aleksi Tornio, Tuija Tapaninen, Maria Paile‐Hyvärinen, Mikko Neuvonen, Janne T. Backman, Mikko Niemi

    The aim of this study was to search for associations of genetic variants with celiprolol pharmacokinetics in a large set of pharmacokinetic genes, and, more specifically, in a set of previously identified candidate genes ABCB1, SLCO1A2, and SLCO2B1. To this end, we determined celiprolol single-dose (200 mg) pharmacokinetics and sequenced 379 pharmacokinetic genes in 195 healthy volunteers. Analysis with 46,064 common sequence variants in the 379 genes did not identify any novel genes associated with celiprolol exposure. The candidate gene analysis showed that the ABCB1 c.3435T>C and c.2677T/G>A, and the SLCO1A2 c.516A>C variants were associated with reduced celiprolol area under the plasma concentration-time curve (AUC0–∞). An alternative analysis with ABCB1 haplotypes showed that, in addition to SLCO1A2 c.516A>C, three ABCB1 haplotypes were associated with reduced celiprolol AUC0–∞. A genotype scoring system was developed based on these variants and applied to stratify the participants to low and high celiprolol exposure genotype groups. The mean AUC0–∞ of celiprolol in the low exposure genotype group was 55% of the mean AUC0–∞ in the high exposure group (p = 1.08 × 10−11). In addition, the results showed gene-gene interactions in the effects of SLCO1A2 and ABCB1 variants on celiprolol AUC0–∞ (p < 5 × 10−6) suggesting an interplay between organic anion transporting polypeptide 1A2 and P-glycoprotein in celiprolol absorption. Taken together, these data indicate that P-glycoprotein and organic anion transporting polypeptide 1A2 play a role in celiprolol pharmacokinetics. Furthermore, patients with ABCB1 and SLCO1A2 genotypes associated with low celiprolol exposure may have an increased risk of poor blood-pressure lowering response to celiprolol.


  • Open Access

    UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics—A Comprehensive Pharmacogenomic Study

    by Päivi Hirvensalo, Aleksi Tornio, Terhi Launiainen, Maria Paile‐Hyvärinen, Tuija Tapaninen, Mikko Neuvonen, Janne T. Backman, Mikko Niemi

    To investigate how variability in multiple pharmacokinetic genes associates with telmisartan exposure, we determined telmisartan single‐dose (40 mg) pharmacokinetics and sequenced 379 genes in 188 healthy volunteers. Intronic UGT1A variants showed the strongest associations with the area under the plasma concentration‐time curve from zero hours to infinity (AUC0–∞) and peak plasma concentration (Cmax) of telmisartan. These variants were strongly linked with the increased function UGT1A3*2 allele, suggesting that it is the causative allele underlying these associations. In addition, telmisartan plasma concentrations were lower in men than in women. The UGT1A3*2 was associated with a 64% and 63% reduced AUC0‐∞ of telmisartan in UGT1A3*2 heterozygous and homozygous men, respectively (P = 1.21 × 10−16 and 5.21 × 10−8). In women, UGT1A3*2 heterozygosity and homozygosity were associated with 57% (P = 1.54 × 10−11) and 72% (P = 3.31 × 10−15) reduced AUC0‐∞, respectively. Furthermore, a candidate gene analysis suggested an association of UGT1A3*3 and the SLCO1B3 c.767G>C missense variant with telmisartan pharmacokinetics. A genotype score, which reflects the effects of sex and genetic variants on telmisartan AUC0–∞, associated with the effect of telmisartan on diastolic blood pressure. These data indicate that sex and UGT1A3 are major determinants and suggest a role for OATP1B3 in telmisartan pharmacokinetics.


  • Open Access

    Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction

    by Tuija Tapaninen, Aleksi M. Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J. Neuvonen, Mikko Niemi, Janne T. Backman

    The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first‐pass metabolism by cytochrome P450 (CYP) 3A4. The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itraconazole on ibrutinib pharmacokinetics. In a randomized crossover study, 11 healthy subjects were administered itraconazole 200 mg or placebo twice on day 1, and once on days 2–4. On day 3, 1 hour after itraconazole (placebo) and breakfast, ibrutinib (140 mg during placebo; 15 mg during itraconazole) was administered. Itraconazole increased the dose‐adjusted geometric mean area under the concentration‐time curve from zero to infinity (AUC0–∞) of ibrutinib 10.0‐fold (90% confidence interval (CI) 7.2–13.9; P < 0.001) and peak plasma concentration (Cmax) 8.8‐fold (90% CI 6.3–12.1; P < 0.001). During itraconazole, the intersubject variation for the AUC0–∞ (55%) and Cmax (53%) was around half of that during placebo (104%; 99%). In conclusion, itraconazole markedly increases ibrutinib bioavailability and decreases its interindividual variability, offering a possibility to improved dosing accuracy and cost savings.


  • Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

    by A Tornio, A M Filppula, O Kailari, M Neuvonen, T H Nyrönen, T Tapaninen, P J Neuvonen, M Niemi, J T Backman

    Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion–transporting polypeptide (OATP)1B1. A recent study revealed an increased risk of rhabdomyolysis in patients using cerivastatin with clopidogrel, warranting further studies on clopidogrel interactions. In healthy volunteers, repaglinide area under the concentration–time curve (AUC0–∞) was increased 5.1–fold by a 300–mg loading dose of clopidogrel and 3.9–fold by continued administration of 75 mg clopidogrel daily. In vitro, we identified clopidogrel acyl–β–D–glucuronide as a potent time–dependent inhibitor of CYP2C8. A physiologically based pharmacokinetic model indicated that inactivation of CYP2C8 by clopidogrel acyl–β–D–glucuronide leads to uninterrupted 60–85% inhibition of CYP2C8 during daily clopidogrel treatment. Computational modeling resulted in docking of clopidogrel acyl–β–D–glucuronide at the CYP2C8 active site with its thiophene moiety close to heme. The results indicate that clopidogrel is a strong CYP2C8 inhibitor via its acyl–β–D–glucuronide and imply that glucuronide metabolites should be considered potential inhibitors of CYP enzymes. Clinical Pharmacology & Therapeutics (2014); 96 4, 498–507. doi:10.1038/clpt.2014.141